Samsung Electronics Co., Ltd.

Samsung Bioepis Co., Ltd.

Mi Young Cho

Kwang Ho Cheong

Seung Hyun Lee

Powei Lin

Jae Woong Hwang

Young Jun Koh

Min-Kyung Kim

Christina Yi

Jung Wook Lee

Hyung-Chan Kim

Kyung Eun Kim

Yoon Sook Lee

Yun Jeong Song

Geun Woong Kim

Han Na Choi

Jae Young Choi

Ji Min Lee

Kyung Ah Kim

Yun Ju Jeong

Soo Yeon Jung

Saet Byoul Lee

Young Mi Oh

Ho Yeong Song

Chanmoo Lee

Lin Powei

Hye Won Park

Yoon Aa Choi

Sangjoon Park

Su Jeong Hwang

An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.

Anti-c-Met/anti-Ang2 bispecific antibody

A fusion polynucleotide including a murine CMV promoter and an intron, a recombinant vector including the fusion polynucleotide and a gene encoding a polypeptide of interest, a recombinant cell including the recombinant vector, and a method of producing a polypeptide of interest using the recombinant vector and/or the recombinant cell.

Fusion polynucleotide containing murine CMV promoter and method of preparing a polypeptide of interest using the same

Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.

Anti-idiotype antibody against anti-c-MET antibody

There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.

Bispecific anti-Cmet/anti-Her2 antibodies

An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.

Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof

An anti-HER2 antibody, an anti-c-Met/anti-HER2 bispecific antibody including the same, method for preparing same, and a method of preventing and/or treating a cancer using the same are provided.

Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same

An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.

Anti-EGFR antibody and anti-c-Met/anti-EGFR bispecific antibodies comprising the same

A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Method of combination therapy using an anti-C-Met antibody

There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for treating cancer using the same, and an anti-EGFR scFv fragment.

Anti-c-Met/anti-EGFR bispecific antibodies

Anti-C-Met/anti-Ang2 bispecific antibody

Provided is an anti-Her3 antibody or antigen-binding fragment thereof, an anti-c-Met/anti-Her3 bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same.

Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same

A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions.

Method of target membrane protein depletion

A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.

Growing community of inventors

Seoul, South Korea

Mi Young Cho